Hong Jun Liang
Director/Board Member chez BEIJING STRONG BIOTECHNOLOGIES,INC.
Profil
Hong Jun Liang is currently the Vice Chairman at Beijing Strong Biotechnologies, Inc. and Director at Fuzhou Maixin Biotech Co., Ltd.
Previously, he served as the Chairman-Supervisory Board at Shanghai Shyndec Pharmaceutical Co., Ltd.
and as a Director at Jiangsu Hengrui Pharmaceuticals Co., Ltd.
from 2018 to 2020.
Postes actifs de Hong Jun Liang
| Sociétés | Poste | Début |
|---|---|---|
| BEIJING STRONG BIOTECHNOLOGIES,INC. | Director/Board Member | 13/08/2020 |
Fuzhou Maixin Biotech Co., Ltd.
 Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The private company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Director/Board Member | 15/09/2020 |
Anciens postes connus de Hong Jun Liang
| Sociétés | Poste | Fin |
|---|---|---|
| JIANGSU HENGRUI MEDICINE CO., LTD. | Director/Board Member | 01/01/2020 |
| SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. | Chairman | 15/11/2019 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| JIANGSU HENGRUI MEDICINE CO., LTD. | Health Technology |
| SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. | Health Technology |
| BEIJING STRONG BIOTECHNOLOGIES,INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Fuzhou Maixin Biotech Co., Ltd.
Fuzhou Maixin Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Part of Beijing Strong Biotechnologies, Inc., Fuzhou Maixin Biotech Co., Ltd. engages in the production, research & development, and sales of tissue-based diagnostics, specifically IHC antibodies, reagents, and the automation of IHC and ISH. The private company is based in Fuzhou, China. Fuzhou Maixin Biotech Co. was acquired by Fuzhou Maixin Biotech Co. Ltd. /Private Group/ on September 30, 2020 for $255.21 million. The Chinese company was founded in 1993. The CEO is Xiao Ya Wang. | Health Services |
